Published in Bone Marrow Transplant on December 01, 1998
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev (2010) 1.28
Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter (2013) 0.87
Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med (1996) 3.30
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol (1989) 2.12
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost (2003) 2.12
Uveitis masquerade syndromes. Ophthalmology (2001) 2.02
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 2.01
Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol (1990) 2.00
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Hypervariable-control-region sequences reveal global population structuring in a long-distance migrant shorebird, the Dunlin (Calidris alpina). Proc Natl Acad Sci U S A (1993) 1.66
Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med (1987) 1.63
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis (1985) 1.45
T-cell receptor V beta-family usage in primary cutaneous and primary nodal T-cell non-Hodgkin's lymphomas. J Invest Dermatol (1992) 1.43
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost (2007) 1.42
[Withdrawing the use of acetylsalicyclic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd (2003) 1.42
How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis (2001) 1.41
High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol (1992) 1.41
[Two patients with hypereosinophilic syndrome]. Ned Tijdschr Geneeskd (2006) 1.39
Three families with polyneuropathy associated with monoclonal gammopathy. Arch Neurol (2000) 1.39
Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med (1995) 1.39
Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood (1994) 1.39
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia (2003) 1.37
A gene expression signature for high-risk multiple myeloma. Leukemia (2012) 1.36
Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol (2000) 1.32
High-resolution HLA-DPB typing based upon computerized analysis of data obtained by fluorescent sequencing of the amplified polymorphic exon 2. Hum Immunol (1993) 1.29
Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med (1981) 1.29
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28
Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation (2003) 1.28
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens (2013) 1.22
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet (1998) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
Sporadic late-onset nemaline myopathy effectively treated by melphalan and stem cell transplant. Neurology (2008) 1.20
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant (2003) 1.16
Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol (2011) 1.14
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia (2011) 1.13
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
[Neurological presentation of non-Hodgkin lymphoma: a diagnostic problem]. Ned Tijdschr Geneeskd (1997) 1.10
Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant (2007) 1.10
Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant (2000) 1.09
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J (2011) 1.07
Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood (1994) 1.06
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol (1998) 1.05
Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol (1992) 1.04
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
A multicenter international evaluation of single-tube amplification protocols for sequencing-based typing of HLA-DRB1 and HLA-DRB3,4,5. Tissue Antigens (2004) 1.02
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Identification and in situ localization of the "thymic nurse cell" in man. J Immunol (1983) 1.01
The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia (2002) 1.01
Detection of cytomegalovirus (CMV) in granulocytes by polymerase chain reaction compared with the CMV antigen test. J Clin Microbiol (1992) 1.01
Allogeneic bone marrow transplantation can restore CD4+ T-lymphocyte count and immune function in idiopathic CD4+ T-lymphocytopenia. Bone Marrow Transplant (1996) 1.00
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia (2010) 1.00
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
MicroRNA signatures characterize multiple myeloma patients. Leukemia (2011) 1.00
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant (2008) 0.98
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 0.98
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation (1993) 0.97
Responses of platelets to strains of streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen-unresponsive patients. Thromb Haemost (1987) 0.97
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia (2003) 0.97
HLA-DO polymorphism associated with resistance to type I diabetes detected with monoclonal antibodies, isoelectric point differences, and restriction fragment length polymorphism. J Exp Med (1986) 0.96
Absence of ligands bound to glycoprotein IIB-IIIA on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest (1994) 0.96
Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. Mol Pathol (2001) 0.95
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia (2011) 0.95
Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia (2005) 0.95
Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol (1997) 0.95
Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol (1996) 0.95